Key result
Gene therapy targeting vasodilator or vasoconstrictor genes controls systemic and pulmonary hypertension in animal models.
Why the study?
Gene therapy has shown promise in animal models for controlling systemic and pulmonary hypertension, but its application in human hypertension control remains to be explored.
Does gene therapy improve control of hypertension in animal models of systemic and pulmonary hypertension?
Does gene therapy improve control of hypertension in animal models of systemic and pulmonary hypertension?
Gene therapy techniques have demonstrated successful long-term control of blood pressure in animal models, suggesting potential feasibility for future human applications in systemic and pulmonary hypertension.
Gene therapy succeeds in animal hypertension models; leaves open translation to human systemic and pulmonary hypertension.
Systemic hypertension is a pathophysiological state that is manifested as high blood pressure and is a major risk factor for stroke, ischemic heart disease, peripheral vascular disease, and progressive renal damage. Pulmonary hypertension occurs in 3 distinct forms: primary pulmonary hypertension, pulmonary hypertension of the newborn, or secondary pulmonary hypertension attributable to a variety of lung and cardiovascular diseases. This review discusses the use of gene therapy in the control of systemic and pulmonary hypertension. Overexpression of vasodilator genes as well as antisense knockdown of vasoconstrictor genes has been successfully used in animal models of both forms of hypertension. Furthermore, the use of viral vectors to deliver these constructs has achieved long-term control of hypertension. The successful establishment of gene therapy techniques in the animal models of hypertension coupled with the anticipated advances in the genetic aspects of this disease would make it highly feasible to attempt gene delivery in the control of human hypertension.
No takes yet. Share an insight, caveat, or question.
Gelband et al. (2000) conducted a review in Systemic and pulmonary hypertension. Gene therapy was evaluated. Gene therapy using overexpression of vasodilator genes or antisense knockdown of vasoconstrictor genes has successfully controlled systemic and pulmonary hypertension in animal models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: